
Society of Thoracic Surgeons

Adult Cardiac Surgery Database

November 4, 2020





Trusted. Transformed. Real-Time.

Agenda

- Welcome and Introductions
- STS Updates and Important Dates
- Capturing Medicare Insurance
- Chronic Lung Disease Coding
- Aorta Devices
- IQVIA Update
- Q&A Please submit using the Q&A function



STS Updates



• Public Reporting

- Next public reporting consent deadline is December 1
 - First quarter 2021
 - Will include 2020 Harvest 1 data (cases through December 31, 2019)
 - All 5 ACSD composite measures will be included
 - Iso CABG, Iso AVR, AVR+CABG, Iso MVRR, and MVRR+CABG
- STS will send notification to sites in the coming weeks
- Contact Sydney Clinton with questions Sclinton@sts.org


• Harvest Updates

- Harvest 1 2020 results updated last weekend
- Harvest 3 2020 is in analysis
- Harvest 4 2020 set to close on November 20
 - STS is discussing a possible extension
 - More information will be sent to sites next week

• AQO Wrap Up

- All AQO Sessions will be available for an entire year
- CE Credit must be claimed by December 31, 2020
- Access to AQO will be available for purchase in late November via the STS Learning Center for those who did not attend

Important Dates for Adult Cardiac







Capturing Medicare Insurance

- Medicare
 - Plan A Hospital Insurance
 - Inpatient Hospital Stays
 - SNF
 - Hospice
 - Some Home Health Care
 - Plan B Medical Insurance (Fee For Service)
 - Doctor Services
 - Outpatient Care
 - Medical Supplies
 - Preventive Services
 - Plan C Medicare Advantage
 - Commercial Alternative to Medicare Plans A & B
 - Patient forgoes Plan A and B and pays a Commercial Insurance provider for coverage
 - Plan D- Prescription Drug Coverage
 - Plan E Medigap or Supplemental Insurance
 - Discontinue to new enrollees in 2010
 - In addition to Traditional Medicare
 - Plan F, G, N Medigap or Supplemental Insurance
 - In addition to Traditional Medicare

Capturing Medicare Insurance


- Plan C Medicare Advantage
 - Commercial Alternative to Medicare Plan A & B
 - Patient forgoes Plans A and B and pays a Commercial Insurance provider for coverage
 - If this is primary, then code
 - Commercially Manager Medicare Plan "Yes" and
 - Primary Payor Medicare Part B "No"
- Supplemental Plans
 - Plan E Medigap or Supplemental Commercial Insurance
 - Discontinue to new enrollees in 2010
 - In addition to Traditional Medicare A & B
 - Plans F, G, N Medigap or Supplemental Commercial Insurance
 - All in addition to Traditional Medicare A & B
 - For those with Primary Medicare then code
 - Commercially Managed Medicare as "No"
 - Primary Payor Medicare Part B as "Yes"
 - Code Secondary as either Commercial Health Insurance or HMO which ever is appropriate
- Patients who are still working or in special situations may have a commercial or HMO insurance as
 primary, which is not a Medicare advantage plan, and may also have Medicare, which would be coded
 as a secondary
 - You need to look to make sure the commercial or HMO insurance is not a Medicare advantage plan



Medicare Primary with Commercial Supplement

meuloare dia not cover.	C. Hospitalization			
MUTUAL OF OMAHA INSURANCE COMPANY	Hospital Name: (If Not Missing →) HospName (205)		spital ZIP Code: Hospital Region: spZIP (210) HospStat (215)]
INSURANCE IDENTIFICATION CARD	Hospital National Provider Identifier: HospNPI (220)		spital CMS Certification Number: spCMSCert (221)	
Coverage Number:	Primary Payor: ** (Choose one↓) PayorPrim (291)	(If	Primary Payor <> None/Self 1) Secondary Payor: ** (Choose one) PayorSecond (298)	
Coverage Type: MEDICARE SUPPLEMENT PLAN G	□ None/Self		None/Self	
Please isit us at: www.mutualofomaha.com	Medicare (includes commercially managed options)		Medicare (includes commercially managed options)	
MEDICARE HEALTH INSURANCE Name/Nombre Medicare Number/Número de Medicare Medicare Number/Número de Medicare Medicare Number/Número de Medicare	(If Medicare →) Commercially Managed Medicare Plan ComMngMedPlnPrim (292) □Yes □ No (If No ↓) HICN/MBI Known HICN/MBIKnown (293) □ Yes □ No (If Yes ↓) HICN/MBI HICN/MBI HICN/MBI Primary Payor Medicare Part B: □Yes) □ No PrimMCareFFS (295)		(If Medicare →) Commercially Managed Medicare Plan ComMngMedPlnSec (299) □Yes □ No (If No ↓) HICN/MBI Known HICNMBIKnownSec (300) □ Yes □ No (If Yes ↓) HICN/MBI: HICN/MBI: HICN/MBI: HICN/MBI: HICN/MBI: HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI HICN/MBISI Commercially Managed Medicare Plan	
MEDICAL (PART B) 02-01-2011	Medicaid (includes commercially managed options)	-	Medicaid (includes commercially managed options)	4
	Commercial Health Insurance	V	Commercial Health Insurance	4
STATUOR THORACIC SHERE	Health Maintenance Organization MEDICARE HEALTH INSURANCE Name/Nombre Entitle Korcon derecho a HOSPITAL (PART A) MEDICAL (PART A)	1	Health Maintenance Organization Medicare Supplement Plans UnitedHealthcare Company ARP MEDICARE SUPPLEMENT PLAN F	
Etrablished 1964			sts.org	

Medicare Advantage Commercially Managed Medicare Plan






Chronic Lung Disease

- You may use DLCO or DLCO/VA to determine CLD
- Code the worse identified level of severity
 - DLCO/DLCO V/A
 - FEV1
 - ABG
- Starting with November 1 cases
- Refer to the Training Manual will be posted by early next week

Aorta Devices

- Starting with November 1 cases, please enter in the Model Number
- This captures the size of the device
- Too many devices and too many sizes of a device to enter using harvest codes or size fields
- This is a free-text field
- Composite Grafts
 - Enter under AVAVCompGraftImpIAo
 - Will open ADEVLoc01
 - If no other devices were inserted, then leave ADEVLoc01 blank





IQVIA Update Joe Brower & Melanie Bent



sts.org

November 2020 Release Updates

The following updates are targeted to be release the weekend of November 7

- ACSD Participant Dashboard Report
 - STS-2994 IMA(Internal Mammary Artery) used displaying incorrect case count
 - Duplicate to item above STS-2219 Dashboard IMA Used case count
 - Duplicate to item above STS-2068 Dashboard IMA Used
 - STS-3581 Dashboard Graphs is not matching for discharge/mortality
 - Duplicate to item above STS-3387 Dashboard report percentages showing 0%

Missing Variable Report

- STS-3419 Inconsistent number returning for SSN data element, parent logic updated
- STS-3603 MVR indicates variables are missing but values are present on the form; Dialysis, Warfarin, Direct Thrombin Inhibitors
- STS-1864 Missing Variable Report showing variables initial extubation date/time as missing, but values are present on the form





New Enhancements

ACSD Uploader Validation Enhancements

The following updates are targeted to be release the **weekend of November 7**

Critical error validations added to the following fields if they are missing in the uploader file submission:

- Surgeon NPI
- Hospital NPI
- *Primary Anesthesia NPI (if site opted in for Anesthesia program)

Records will be dropped if these fields are missing.

Applicable for data versions 2.81/2.9/4.20.2



November 2020 Release Updates Con't

The following updates are targeted to be release the weekend of November 7

ACSD Participant Dashboard Report (non-analyzed) Updates


Updates will be applied to incorporate data mapping for identified variables between the 4.20.2/2.9/2.81 versions

- Update applied to incorporate the 4.20.2 Procedure Identification updates to the procedure filtering on the dashboard.
- Update applied to report logic to exclude patients identified as "in hospital-alive" from procID assignment using 4.20.2 variable (dischmtptacutehospstill)
- Update applied to incorporate display label changes to existing variables
- Updates include new fields on the Discharge/Mortality Report section
 - Hospital Discharge Date
 - Missing percentage added
 - Mortality Date
 - Missing percentage added



ACSD 4.20.2 Dashboard Variables

- Race Variable Mapping for handling 4.20.2 and previous versions
- The dashboard will display selected date range with cross over results for multiple data versions in the case drill down



sts.org



ACSD 4.20.2 ProcID Filter Logic Updated

• The ACSD dashboard procedure parameter filter has been updated to align with the changes made for the 4.20.2 PROCID chart.

Reporting Period						Date Range						
Select					~	07/01/2020		to	10/01/2020			
: File Edit Visu	ualizations Viev	N	Tools User									
Select Report:				My Site		SEX » FEMALE			My Site		RACE V	AM INDIAN/A
DEMOGRAPHICS						SEX » MALE					RACE	
HOSPITALIZATION RISK FACTORS PREOPERATIVE CARDIAC			41.25	53.75	100.00	SEX » MISSING		15.75	69.29	100.79	RACE 3	BLACK/AFRI HAWAIIAN/P
PREOPERATIVE MEDICATI HEMODYNAMICS/CATH/EC				STS					STS			MULTIPLE R
OPERATIVE	.110										RACE a	OTHER
VALVE SURGERY MECHANICAL CARDIAC A			41.25	53.75	100.00			15.75	69.29	100.00	RACE 3	WHITE
OTHER CARDIAC PROCED OTHER NON-CARDIAC PRO												
POST-OPERATIVE POSTOPERATIVE EVENTS											My Site	
DISCHARGE / MORTALITY			DEMOGR	RAPHICS	NUMB	ER OF CASES	NUMBER OF CA	SES		1	60	160
READMISSION					PA	TIENT AGE	65-79			1	4 (8.8%)	14 (8.8%
- ALCONICON							80+			1	(0.6%)	1 (0.6%)
							AGE < OR EQU	L TO 55 (MALE	Ξ)	5	8 (36.3%)	58 (36.3
	Patient ID		Access Case		Surgery Da	ite Variabl	e Vari	able Option	Report Name	RECORDID	(50.6%)	81 (50.69
		ttps://s	sts-uat1.irp.iqvia.com/platfo		8/8/2020	NUMBER OF	CASES NUMB	ER OF CASES	DEMOGRAPHICS	V6901118	(38.8%)	62 (38.89
			sts-uat1.irp.iqvia.com/platfo		8/24/2020			ER OF CASES	DEMOGRAPHICS	V6901139	(37.5%)	60 (37.59
		and the second second	sts-uat1.irp.iqvia.com/platfo		8/2/2020	NUMBER OF NUMBER OF		ER OF CASES ER OF CASES	DEMOGRAPHICS DEMOGRAPHICS	V6901112 V6901117	(13.8%)	22 (13.89
			<u>sts-uat1.irp.iqvia.com/platfo</u> sts-uat1.irp.iqvia.com/platfo		8/7/2020 8/19/2020			ER OF CASES	DEMOGRAPHICS	V6901117 V6901129		
			sts-uat1.irp.iovia.com/platfo		8/13/2020	NUMBER OF		ER OF CASES	DEMOGRAPHICS	V6901123	(9.4%)	15 (9.4%
	V9900045 ht	ttps://s	sts-uat1.irp.iqvia.com/platfo	rm/acsdregistry/faci	8 <mark>/24/2020</mark>	NUMBER OF	CASES NUMB	ER OF CASES	DEMOGRAPHICS	V6901145	0.0%)	0 (0.0%)
			sts-uat1.irp.iqvia.com/platfo		8/6/2020	NUMBER OF		ER OF CASES	DEMOGRAPHICS	V6901116	(53.8%)	86 (53.8
	V9900014 ht		sts-uat1.irp.igvia.com/platfo		8/4/2020			ER OF CASES	DEMOGRAPHICS	V6901114	,	
			ats-uat1.irp.iqvia.com/platfo ats-uat1.irp.iqvia.com/platfo	Contraction of the second second	8/1/2020 8/24/2020	NUMBER OF NUMBER OF		ER OF CASES ER OF CASES	DEMOGRAPHICS DEMOGRAPHICS	V6901111 V6901160		Report Nan
	V9900011	ttoo://o		minacouregistry/faci				ER OF CASES	DEMOGRAPHICS	V6901125	ES	DEMOGRAPH
	V9900011 ht		sts-uat1.irp.iovia.com/platfo	rm/acsdregistry/faci								
	V9900011 h V9900060 h V9900025 h	ttps://s			8/15/2020 8/24/2020		CASES NUMB	ER OF CASES	DEMOGRAPHICS	V6901143		
	V9900011 ht V9900060 ht V9900025 ht V9900043 ht	ttps://s ttps://s	sts-uat1.irp.iqvia.com/platfo	rm/acsdregistry/faci				ER OF CASES ER OF CASES	DEMOGRAPHICS DEMOGRAPHICS	V6901143 V6901154		
	V9900011 h V9900060 h V9900025 h V9900043 h V9900054 h	ttps://s ttps://s ttps://s ttps://s	sts-uat1.irp.iqvia.com/platfo sts-uat1.irp.iqvia.com/platfo sts-uat1.irp.iqvia.com/platfo sts-uat1.irp.iqvia.com/platfo	rm/acsdregistry/faci rm/acsdregistry/faci rm/acsdregistry/faci	8/24/2020 8/24/2020 8/24/2020	NUMBER OF NUMBER OF NUMBER OF	CASES NUMB CASES NUMB	ER OF CASES ER OF CASES	DEMOGRAPHICS DEMOGRAPHICS	V6901154 V6901159		
K. S.	V9900011 h V9900060 h V9900025 h V9900043 h V9900054 h V9900059 h	ttps://s ttps://s ttps://s ttps://s ttps://s	sts-uat1.irp.iqvia.com/platfo sts-uat1.irp.iqvia.com/platfo sts-uat1.irp.iqvia.com/platfo sts-uat1.irp.iqvia.com/platfo sts-uat1.irp.iqvia.com/platfo	rm/acsdregistry/faci rm/acsdregistry/faci rm/acsdregistry/faci rm/acsdregistry/faci	8/24/2020 8/24/2020 8/24/2020 8/24/2020	NUMBER OF NUMBER OF NUMBER OF NUMBER OF	CASES NUMB CASES NUMB CASES NUMB	ER OF CASES ER OF CASES ER OF CASES	DEMOGRAPHICS DEMOGRAPHICS DEMOGRAPHICS	V6901154		
K STAR	V9900011 h V9900060 h V990025 h V990043 h V9900054 h V9900059 h V9900059 h	ttps://s ttps://s ttps://s ttps://s ttps://s ttps://s	ats-uat1.irp.jqvia.com/platfo sts-uat1.irp.jqvia.com/platfo sts-uat1.irp.jqvia.com/platfo sts-uat1.irp.jqvia.com/platfo sts-uat1.irp.jqvia.com/platfo sts-uat1.irp.jqvia.com/platfo	m/acsdregistry/faci m/acsdregistry/faci m/acsdregistry/faci m/acsdregistry/faci m/acsdregistry/faci	8/24/2020 8/24/2020 8/24/2020 8/24/2020 8/24/2020 8/3/2020	NUMBER OF NUMBER OF NUMBER OF NUMBER OF NUMBER OF	CASES NUME CASES NUME CASES NUME CASES NUME	ER OF CASES ER OF CASES ER OF CASES ER OF CASES	DEMOGRAPHICS DEMOGRAPHICS DEMOGRAPHICS DEMOGRAPHICS	V6901154 V6901159 V6901148		
A SIL RECONS	V9900011 h V9900060 h V9900025 h V9900043 h V9900054 h V9900059 h V9900048 h V9900048 h	ttps://s ttps://s ttps://s ttps://s ttps://s ttps://s	sts-uat1.irp.iqvia.com/platfo sts-uat1.irp.iqvia.com/platfo sts-uat1.irp.iqvia.com/platfo sts-uat1.irp.iqvia.com/platfo sts-uat1.irp.iqvia.com/platfo	rm/acsdregistry/faci rm/acsdregistry/faci rm/acsdregistry/faci rm/acsdregistry/faci rm/acsdregistry/faci rm/acsdregistry/faci	8/24/2020 8/24/2020 8/24/2020 8/24/2020	NUMBER OF NUMBER OF NUMBER OF NUMBER OF NUMBER OF	CASES NUME CASES NUME CASES NUME CASES NUME CASES NUME	ER OF CASES ER OF CASES ER OF CASES	DEMOGRAPHICS DEMOGRAPHICS DEMOGRAPHICS	V6901154 V6901159		

eports elect each report title below to view report specific parameters and gen	erate data. Some reports have sub-rep
arameters	
Time Period Procedures	
Procedures	
Select one or more	
All	<u>^</u>
Isolated Coronary Artery Bypass (CABG)	
CAB: On-pump procedures	
CAB: Off-pump procedures	
CAB: Off-pump procedures	



ACSD 4.20.2 Dashboard Updates

Reports

Select each

- Hospital Discharge Date
 - Missing percentage added
- Mortality Date
 - Missing percentage added

Edit Visual	izations View Tools User			
			My Site	STS
	BETA BLOCKER	CONTRAINDICATED	0 (0.0%)	0 (0.0%)
		MISSING	0 (0.0%)	0 (0.0%)
		NO	26 (23.2%)	26 (23.2%)
		YES	86 (76.8%)	86 (76.8%)
	LIPID LOWERING - STATIN	CONTRAINDICATED	0 (0.0%)	0 (0.0%)
		MISSING	0 (0.0%)	0 (0.0%)
		NO	86 (76.8%)	86 (76.8%)
		YES	26 (23.2%)	26 (23.2%)
	LIPID LOWERING - OTHER	CONTRAINDICATED	26 (23.2%)	26 (23.2%)
		MISSING	0 (0.0%)	0 (0.0%)
		NO	0 (0.0%)	0 (0.0%)
		YES	86 (76.8%)	86 (76.8%)
	OPERATIVE MORTALITY	MISSING	0 (0.0%)	0 (0.0%)
		NO	0 (0.0%)	0 (0.0%)
		YES	88 (77.2%)	88 (77.2%)
	HOSPITAL DISCHARGE DATE	MISSING	0 (0.0%)	0 (0.0%)
	MORT-STATUS AT 30 DAYS AFTER	ALIVE	63 (39.1%)	63 (39.1%)
	SURGERY (EITHER DISCHARGED OR IN-HOSPITAL):	DEAD	86 (53.4%)	86 (53.4%)
		MISSING	11 (6.8%)	11 (6.8%)
		UNKNOWN	1 (0.6%)	1 (0.6%)
	MORTALITY - DATE	MISSING	0 (0.0%)	0 (0.0%)
	STATUS AT HOSPITAL DISCHARGE:	DIED IN HOSPITAL	2 (1.8%)	2 (1.8%)
		DISCHARGED ALIVE, DIED AFTER DISCHARGE	112 (98.2%)	112 (98.2%)
		DISCHARGED ALIVE, LAST KNOWN STATUS ALIVE (OTHER THA	0 (0.0%)	0 (0.0%)
		DISCHARGED TO HOSPICE	0 (0.0%)	0 (0.0%)
		IN HOSPITAL, ALIVE	0 (0.0%)	0 (0.0%)
		MISSING	0 (0.0%)	0 (0.0%)



ACSD Participant Dashboard Report

New Report MIPS 2020 Performance Measures Demo Coming this weekend



MIPS 2020 Performance Measures

- Surgeons and delegates can now review their current MIPS 2020 measure status using the new MIPS Performance Measures interactive Dashboard.
- Surgeons who consent via the electronic consent form will have the ability to access and review their 2020 quarterly results.
- The STS will report results on the behalf of consenting surgeons for 9 identified Adult Cardiac quality measures to CMS.
 - Please reference the STS.org website for further details -<u>https://www.sts.org/registries-research-center/sts-national-database/mips-reporting</u>



MIPS 2020 Performance Measures Dashboard

- The MIPS 2020 Report is an interactive dashboard
- Near-real time case data available for surgeon review
- UAT was successfully completed by identified surgeons
 - Feedback
 - "Easy to use!"
 - "Looks great!"
 - "Report is intuitive and like the drill down capability to review cases that are identified as performance not met."



MIPS 2020 Performance Measure Report

		IIPS Perfor The Merit-bas			n (MIPS) reno	rt will provide re	esults for all a	vailable (case data t	for the identif	ied MIPS meas	sures during the r	reportir
Ø Operational Reports		eriod.				, in provide it						aree aanny are i	oporti
ACSD Reports													
MIPS Performance Measures Re	port												
													+
File Edit Data	Visualizations	s View Tools	User									🔷 🛱 T	Expan
Participant ID: 17410 Re	porting Period:	2020 TIN: 903	8003104 NPI- 100	03003104 Surgeon Na	ame: SMITH, ZADIE								
and paneto. 17410	porting renou.	2020 111. 500		Sugeria		rmance Measures §	Summary - 2020						
					Q1.2020	Q4.20	20						
					J								
80.00%						66.67%							
60.00% -													
60.00% -											52.38%		
											52.38%		
60.00%											52.38%		
40.00% -											52.38%		
40.00% -	.31%									10.58%	52.38%		
40.00% - 20.00% - 11	1.31%	2.38%	1.79%	1.80%	0.65%		4.38%		1 43%	10.58%	52.38%	5.66%	
40.00% - 20.00% - 11 0.00%			1.79%	1.80%					1.43%				
40.00% - 20.00% - 11 0.00%	MORTALITY*	2.38% CABG: PROLONGED INTUBATION*	1.79% CABG: PROLONGE LENGTH OF STAY*			PATIENT-CENTERED RISKASSESSMENT	PREOPERATIVE BE BLOCKER IN PATIEN	TA- SELECTIO	ON OF ACTIC	TOBACCO USE: SCREENING AND	TOBACCO USE: SCREENING AND	TOBACCO USE: SCREENING AND	
40.00% - 20.00% - 11 0.00%	MORTALITY*	CABG: PROLONGED	CABG: PROLONGE		CABG: UNPLANNED	PATIENT-CENTERED RISK ASSESSMENT USING STS RISK	PREOPERATIVE BE BLOCKER IN PATIEN WITH ISOLATED CA	TA- SELECTIO	ON OF ACTIC IC - FIRST OR	TOBACCO USE: SCREENING AND CESSATION	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE: SCREENING AND CESSATION	
40.00% - 20.00% - 11 0.00%	MORTALITY*	CABG: PROLONGED	CABG: PROLONGE		CABG: UNPLANNED	PATIENT-CENTERED RISKASSESSMENT	PREOPERATIVE BE BLOCKER IN PATIEN	TA- SELECTIO	ON OF ACTIC	TOBACCO USE: SCREENING AND	TOBACCO USE: SCREENING AND	TOBACCO USE: SCREENING AND	
40.00% - 20.00% - 0.00% - CABG: OP	MORTALITY*	CABG: PROLONGED INTUBATION*	CABG: PROLONGE LENGTH OF STAY*	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION*	PATIENT-CENTERED RISKASSESSMENT USING STRISK CALCULATOR	PREOPERATIVE BE BLOCKER IN PATIEN WITH ISOLATED CA SURGERY	TA- SELECTIO	ON OF ACTIC IC - FIRST OR	TOBACCO USE: SCREENING AND CESSATION	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE: SCREENING AND CESSATION	
40.00% - 20.00% - 11 0.00%	MORTALITY*	CABG: PROLONGED INTUBATION*	CABG: PROLONGE LENGTH OF STAY*	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION*	PATIENT-CENTERED RISKASSESSMENT USING STRISK CALCULATOR	PREOPERATIVE BE BLOCKER IN PATIEN WITH ISOLATED CA SURGERY	TA- SELECTIO	ON OF ACTIC IC - FIRST OR	TOBACCO USE: SCREENING AND CESSATION	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE: SCREENING AND CESSATION	
40.00% - 20.00% - 0.00% - CABG: OP	MORTALITY*	CABG: PROLONGED INTUBATION* erse" measures, which Performance Rate	CABG: PROLONGE LENGTH OF STAY* means a lower calculate Eligible Population	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION*	PATIENT-CENTERED RISKASSESSMENT USING STR RISK CALCULATOR ecoses, a performance rate formance Not Met	PREOPERATIVE BE BLOCKER IN PATIEN WITH ISOLATED CA SURGERY	TA- SELECTION NTS PROPHYL BG ANTIBIOT SECOND	DN OF ACTIC IC - FIRST OR -GENERATION	TOBACCO USE: SCREENING AND CESSATION	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE: SCREENING AND CESSATION	
40.00% - 20.00% - 0.00% - CABG: OP (*) Indicates Measures that are do	MORTALITY* esignated as "inve Time Period Q3.2020	CABG: PROLONGED INTUBATION* erse" measures, which Performance Rate 6.25%	CABG: PROLONGE LENGTH OF STAY* means a lower calculate Eligible Population E 64	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION*	PATIENT.CENTERED RISKASSESSMENT USING STS RISK CALCULATOR eccess, a performance rate fformance Not Met 60	PREOPERATIVE BE BLOCKER IN PATIEN WITH ISOLATED CA SURGERY closer to 0% is better. Display Case List T Time Period P	TA- SELECTIC ITS PROPHY BG ANTIBIOT SECOND abular Section atient Record ID	DN OF ACTIC IC - FIRST OR -GENERATION	TOBACCO USE: SCREENING AND CESSATION	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE: SCREENING AND CESSATION	Acces
40.00% - 20.00% - 0.00% - CABG: OP (*) Indicates Measures that are do Measure Name	MORTALITY* esignated as "inve Time Period Q3.2020 Q4.2020	CABG: PROLONGED INTUBATION* rse" measures, which Performance Rate 6.25% 5.00%	CABG: PROLONGE LENGTH OF STAY* means a lower calculate Eligible Population	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION*	PATIENT-CENTERED RISKASSESSMENT USING STR RISK CALCULATOR ecoses, a performance rate formance Not Met	PREOPERATIVE BE BLOCKER IN PATIEN WITH ISOLATED CA SURGERY closer to 0% is better. Display Case List T Time Period P Q1.2020 11	TA- SELECTIC ITS PROPHYL BG ANTIBIOT SECOND	DN OF ACTIC IC - FIRST OR -GENERATION Measure Name CABG: OP MORT	TOBACCO USE: SCREENING AND CESSATION_1 INTERVENTION_1	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE SCREENING AND CESSATION INTERVENTION_3 Performance Status Performance Nol Met	Acce: https://
40.00% 20.00% 11 0.00% CABG: OP (*) Indicates Measures that are do Measure Name PATIENT-CENTERED RISK	MORTALITY* esignated as "inve Time Period Q3.2020 Q4.2020 Q1.2020	CABG: PROLONGED INTUBATION* erse" measures, which Performance Rate 6.25% 5.00% 0.00%	CABG: PROLONGE LENGTH OF STAY* means a lower calculate Eligible Population E 64	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION*	PATIENT.CENTERED RISKASSESSMENT USING STS RISK CALCULATOR eccess, a performance rate fformance Not Met 60	PREOPERATIVE BE BLOCKER IN PATIEN WITH ISOLATED CA SURGERY closer to 0% is better. Display Case List T Time Period PH 01.2020 PH 01.2020 22	TA- SELECTIC PROPHYL BG ANTIBIOT SECOND	NOF ACTIC IC - FIRST OR GENERATION Measure Name CABG: OP MORT CABG: OP MORT	TOBACCO USE: SCREENING AND CESSATION INTERVENTION_1	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE: SOREENING AND CESSATION INTERVENTION_3 Performance Status Performance Not Met Performance Not Met	https:/ https:/
40.00% - 20.00% - 0.00% - CABG: OP (*) Indicates Measures that are do Measure Name	MORTALITY* signated as "inve Time Period Q3.2020 Q4.2020 Q4.2020 Q2.2020	CABG: PROLONGED INTUBATION* crse" measures, which Performance Rate 6.25% 5.00% 0.00% 75.00%	CABG: PROLONGE LENGTH OF STAY* means a lower calculate Eligible Population E 64	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION*	PATIENT.CENTERED RISKASSESSMENT USING STS RISK CALCULATOR eccess, a performance rate fformance Not Met 60	PREOPERATIVE BE BLOCKER IN PATIES WITH ISOLATED CA SURGERY closer to 0% is better. Display Case List T Time Period P 01 2020 11 01 2020 12 01 2020 11	A- SELECTIC HTS PROPHYL ANTIBIOT SECOND abular Section atient Record ID 54STS1042 56STS1131 38STS1090	NOF ACTIC IC-FIRSTOR GENERATION Measure Name CABG: OP MORT CABG: OP MORT CABG: OP MORT	TOBACCO USE: SCREENING AND CESSATION INTERVENTION_1 INTERVENTION_1	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE SOREENING AND CESSITUM INTERVENTION_3 Performance Not Met Performance Not Met Performance Not Met	https:/ https:/ https:/
40.00% - 20.00% - 11 0.00% - CABG: OP (*) Indicates Measures that are do Measure Name PATIENT-CENTERED RISK ASSESSMENT USING STS RISK	MORTALITY* esignated as "inve Time Period 03.2020 04.2020 04.2020 04.2020 03.2020 03.2020	CABG: PROLONGED INTUBATION* erse" measures, which Performance Rate 6.25% 5.00% 0.00%	CABG: PROLONGE LENGTH OF STAY* means a lower calculate Eligible Population E 64	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION*	PATIENT-CENTERED RISKASSESSMENT USING ST RISK CALCULATOR ecoses, a performance rate formance Not Met 60 19 1 1	PREOPERATIVE BE BLOCKER IN PATIE WITH ISOLATED CA SURGERY closer to 0% is better. Display Case List T Time Period P 01.2020 11 01.2020 22 01.2020 21 01.2020 22	A- SELECTIC ITS PROPHY BG ANTIBIOT SECOND abular Section atient Record ID 54STS1042 26STS1131 38STS1090 26STS1107	N OF ACTIC - FIRST OR GENERATION Measure Name CABG: OP MORT CABG: OP MORT CABG: OP MORT	TOBACCO USE: SCREENING AND CESSATION INTERVENTION_1 FALITY* FALITY* FALITY* FALITY*	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE: SCREENING AND CESSATION INTERVENTION_3 Performance Status Performance Not Met Performance Not Met Performance Not Met	https:/ https:/ https:/ https:/
40.00% 20.00% CABG: OP CABG: O	MORTALITY* esignated as "inve Time Period Q3.2020 Q4.2020 Q4.2020 Q3.2020 Q3.2020 Q4.2020 Q4.2020 Q4.2020	CABG: PROLONGED INTUBATION* erse" measures, which Performance Rate 6.25% 5.00% 75.00% 75.00%	CABG: PROLONGE LENGTH OF STAY* means a lower calculativ Eligible Population E 64 20 1 4 4 0	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION*	PATENT.CENTERED RISK ASSESSMENT USING STS RISK CALCULATOR romance Not Met 60 19 1 1 1 1 0	PREOPERATIVE BE BLOCKER IN PATIE WITH ISOLATED CA SURGERY Closer to 0% is better. Display Case List T Time Period P 01 2020 22 01 2020 11 01 2020 22 01 2020 44	TA- SELECTIC ITS PROPHY ISG ANTIBIOT SECOND abular Section atient Record ID 545TS1042 265TS1131 385TS1090 265TS1107 45TS1058	N OF ACTIC C - FIRST OR -GENERATION CABG: OP MORI CABG: OP MORI CABG: OP MORI CABG: OP MORI CABG: OP MORI CABG: OP MORI	TOBACCO USE: SCREENING AND CESSATION INTERVENTION_1 INTERVENTION_1 AUTY* FALITY* FALITY* FALITY*	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE SOREENING AND CESSATION INTERVENTION_3 Performance Not Met Performance Not Met Performance Not Met Performance Not Met Performance Not Met	https:/ https:/ https:/
40.00% 20.00% 20.00% CABG: OP (*) Indicates Measures that are do (*) Indicates Measure Name PATIENT-CENTERED RISK ASSESSMENT USING STS RISK CALCULATOR PREOPERATIVE BETA-BLOCKEI	MORTALITY* esignated as "inve Time Period Q3.2020 Q4.2020 Q4.2020 Q2.2020 Q3.2020 Q3.2020 R Q4.2020 R Q1.2020	CABG: PROLONGED INTUBATION* Performance Rate 6.25% 5.00% 7.5.00% 7.5.00% 2.78%	CABG: PROLONGE LENGTH OF STA/* means a lower calculate Eligible Population E 4 20 1 4 4 3 6	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION*	PATIENT-CENTERED RISKASSESSMENT USING ST MSK CALCULATOR e coses, a performance rate formance Not Met 60 19 1 1 1 1 1 35	PREOPERATIVE BE BLOCKER IN PATIEN WITH ISOLATED CA SURGERY closer to 0% is better. Display Case List T Time Period P 01 2020 11 01 2020 22 01 2020 22 01 2020 22 01 2020 24 01 2020 4	A. SELECTIC ITS PROPHY BG ANTIBIO SECOND abular Section atient Record ID 34STS1042 26STS1131 38STS1090 26STS1107 4STS1058 15STS1110	N OF ACTIC - FIRST OR GENERATION Measure Name CABG: OP MORT CABG: OP MORT CABG: OP MORT	TOBACCO USE: SCREENING AND CESSATION INTERVENTION_1 INTERVENTION_1 AUTY* FALITY* FALITY* FALITY*	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE: SCREENING AND CESSATION INTERVENTION_3 Performance Status Performance Not Met Performance Not Met Performance Not Met	https:/ https:/ https:/ https:/
40.00% 20.00% 20.00% CABG: OP CABG: OP (*) Indicates Measures that are do CABG: OP (*) Indicates Measures that are do CABG: OP CABG: OP	MORTALITY* esignated as "inve Time Period 03.2020 04.2020 04.2020 04.2020 04.2020 04.2020 04.2020 04.2020 02.2020	CABG: PROLONGED INTUBATION* rse" measures, which Performance Rate 6.25% 5.00% 75.00% 75.00% 2.78% 6.62%	CABG: PROLONGE LENGTH OF STAY* means a lower calculate Eligible Population E 64 20 1 4 4 0 36 44	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION*	PATIENT-CENTERED RISKASSESSMENT USING STS RISK CALCULATOR romance Not Met formance Not Met 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	PREOPERATIVE BE BLOCKER IN PATIEN WITH ISOLATED CA SURGERY closer to 0% is better. Display Case List T Time Period 01.2020 11 01.2020 21 01.2020 21 01.2020 22 01.2020 22 01.2020 4	TA- SELECTIC ITS PROPHY ISG ANTIBIOT SECOND abular Section atient Record ID 545TS1042 265TS1131 385TS1090 265TS1107 45TS1058	N OF ACTIC C - FIRST OR -GENERATION CABG: OP MORI CABG: OP MORI CABG: OP MORI CABG: OP MORI CABG: OP MORI CABG: OP MORI	TOBACCO USE: SCREENING AND CESSATION INTERVENTION_1 FALITY* FALITY* FALITY* FALITY* FALITY* FALITY*	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE SOREENING AND CESSATION INTERVENTION_3 Performance Not Met Performance Not Met Performance Not Met Performance Not Met Performance Not Met	https:/ https:/ https:/ https:/ https:/
40.00% 20.00% 20.00% CABG: OP (*) Indicates Measures that are do (*) Indicates Measure Name PATIENT-CENTERED RISK ASSESSMENT USING STS RISK CALCULATOR PREOPERATIVE BETA-BLOCKEI	MORTALITY* sesignated as "inved Time Period Q3.2020 Q4.2020 Q4.2020 Q2.2020 Q4.2020 R Q1.2020 R Q1.2020 Q2.2020 Q3.2020 Q3.2020 C3.2020 C3.2020 C3.2020 C3.2020 C3.2020 C3.2020 C3.2020 C3.2020 C3.2020 C3.2020 C3.2020 C3.2020 C3.2020 C3.2020 C3.2020 C3.2020	CABG: PROLONGED INTUBATION* rse" measures, which Performance Rate 6.25% 5.00% 75.00% 2.78% 6.62% 3.23%	CABG: PROLONGE LENGTH OF STAY* means a lower calculate Eligible Population E 64 20 1 4 4 4 36 36 44 62	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION*	BATENT-CENTERED RISK ASSESSMENT USING STS RISK CALCULATOR et cases, a performance rate formance Not Met 10 11 1 1 1 0 35 41 60	PREOPERATIVE BE BLOCKER IN PATIE WITH ISOLATED CA SURGERY Closer to 0% is better. Display Case List T Time Period P 0.1 2020 21 0.1 2020 21 0.1 2020 44 0.1 2020 42 0.1 2020 44 0.1 2020 22	A. SELECTIC ITS PROPHY BG ANTIBIO SECOND abular Section atient Record ID 34STS1042 26STS1131 38STS1090 26STS1107 4STS1058 15STS1110	N OF ACTIC - FIRST OR GENERATION Measure Name CABG: OP MORT CABG: OP MORT CABG: OP MORT CABG: OP MORT CABG: OP MORT CABG: OP MORT	TOBACCO USE: SCREENING AND CESSATION INTERVENTION_1 FAILTY* FAILTY* FAILTY* FAILTY* FAILTY* FAILTY*	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE SCREENING AND CESSITION INTERVENTION_3 Performance Status Performance Not Met Performance Not Met Performance Not Met Performance Not Met Performance Not Met	https:/ https:/ https:/ https:/ https:/ https:/
40.00% 20.00% 20.00% CABG: OP (*) Indicates Measures that are do CABG: OP (*) Indicates Measures that are do Measure Name PATIENT-CENTERED RISK ASSESSMENT USING STS RISK CALCULATOR PREOPERATIVE BETA-BLOCKEI IN PATIENTS WITH ISOLATED CABG SURGERY	MORTALITY* esignated as "inve Time Period Q3.2020 Q4.2020 Q4.2020 Q3.2020 Q4.2020 Q4.2020 Q2.2020 Q2.2020 Q2.2020 Q2.2020 Q3.2020 Q4.2020	CABG: PROLONGED INTUBATION* rse* measures, which Performance Rate 6.25% 5.00% 75.00% 75.00% 6.27% 6.82% 3.23% 5.55%	CABG: PROLONGE LENGTH OF STAY* means a lower calculate Eligible Population E 64 20 1 4 4 0 36 44 62 18	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION*	PATIENT-CENTERED RISKASSESSMENT USING STR RISK CALCULATOR ecoses, a performance rate formance Not Met 60 11 1 1 1 0 35 41 60 17	PREOPERATIVE BE BLOCKER IN PATIE WTH ISOLATED CA SURGERY closer to 0% is better. Display Case List T Time Period P 01 2020 22 01 2020 41 01 2020 42 01 2020 44 01 2020 42 01 2020	A SELECTIC ITS PROPHY ANTEINS AUTOR SECOND abular Section attent Record ID 545TS1042 265TS1131 365TS1090 265TS1107 155TS1058 155TS1110 265TS1128	N OF ACTIC - FIRST OR -GENERATION Measure Name CABG: OP MORT CABG: OP MORT CABG: OP MORT CABG: OP MORT CABG: OP MORT CABG: OP MORT	TOBACCO USE: SCREENING AND CESSATION INTERVENTION_1 FALITY* ALITY* ALITY* ALITY* ALITY* ALITY* ALITY* ALITY* ALITY*	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE: SOREENING AND CESSATION INTERVENTION_3 Performance Not Met Performance Not Met Performance Not Met Performance Not Met Performance Not Met Performance Not Met Performance Not Met	https:/ https:/ https:/ https:/ https:/ https:/
40.00% 20.00% 20.00% CABG: OP (*) Indicates Measures that are di CABG: OP (*) Indicates Measure Name PATIENT-CENTERED RISK ASSESSMENT USING STS RISK CALCULATIOR PREOPERATIVE BETA-BLOCKEE IN PATIENT'S WITH ISOLATED CABG SURGERY SELECTION OF PROPHYLACTIO	MORTALITY* Time Period O3.2020 O4.2020 O4.2020 O4.2020 O4.2020 C4.2020 O4.2020 O3.2020 O4.2020 O3.2020 O3.2020 O3.2020 O4.2020 O3.2020 O4.2020 O3.2020 O4.2020 O4.20	CABG: PROLONGED INTUBATION* rsc* measures, which Performance Rate 6 .25% 5 .00% 7 5 .00% 7 5 .00% 2 .27% 6 .82% 3 .23% 5 .55% 0 .00%	CABG: PROLONGE LENGTH OF STAV ^a means a lower calculation Eligible Population E 4 20 1 4 4 4 4 62 18 62 18 39	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION*	PATENT-CENTERED RISK ASSESSMENT USING STS RISK CALCULATOR cases, a performance rote fformance Not Met 60 19 1 1 1 1 0 35 41 60 60 17 39	PREOPERATIVE BE BLOCKER IN PATIEN WITH ISOLATED CA SURGERY closer to 0% is better. Display Case List T Time Period Time Period P(12020 12020 12020 12020 012020	A- SELECTIC HTS PROPHY ARTEN SECOND abular Section atient Record ID 265TS1131 385TS1042 265TS1107 45TS1058 455TS1108 455TS1128 265TS1128	N OF ACTIC IC - FIRST OR GENERATION Measure Name CABG: OP MORT CABG: OP MORT CABG: OP MORT CABG: OP MORT CABG: OP MORT CABG: OP MORT CABG: OP MORT	TOBACCO USE SCREENING AND CESSATION INTERVENTION_1 FALITY* FALITY* FALITY* FALITY* FALITY* FALITY* FALITY* FALITY* FALITY* FALITY* FALITY*	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE SCREENING AND CESSATURE INTERVENTION_3 Performance Not Met Performance Not Met	https:/ https:/ https:/ https:/ https:/ https:/ https:/
40.00% 20.00% 20.00% CABG: OP CABG: OP (*) Indicates Measures that are di CABG: OP (*) Indicates Measures that are di Measure Name PATIENT-CENTERED RISK ASSESSMENT USING STS RISK CALCULATOR PREOPERATIVE BETA-BLOCKEI IN PATIENT'S WITH ISOLATED CABG SURGRY SELECTION OF PROPHYLACTIC ANTIBIOTIC - FIRST OR	MORTALITY* esignated as "inve Time Period Q3.2020 Q4.2020 Q4.2020 Q3.2020 Q4.2020 Q4.2020 Q2.2020 Q2.2020 Q2.2020 Q2.2020 Q3.2020 Q4.2020	CABG: PROLONGED INTUBATION* rse* measures, which Performance Rate 6.25% 5.00% 75.00% 75.00% 6.27% 6.82% 3.23% 5.55%	CABG: PROLONGE LENGTH OF STAY* means a lower calculate Eligible Population E 64 20 1 4 4 0 36 44 62 18	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION ⁴⁴ etter clinical care. In these Performance Met Per 4 1 0 3 0 3 3 0 1 3 2 1 1	PATIENT-CENTERED RISKASSESSMENT USING STR RISK CALCULATOR ecoses, a performance rate formance Not Met 60 11 1 1 1 0 35 41 60 17	PREOPERATIVE BE BLOCKER IN PATIE WITH ISOLATED CA SURGERY Closer to 0% is better. Display Case List T Time Period P 01 2020 22 01 2020 11 01 2020 22 01 2020 41 01 2020 22 01 2020 42 01 2020 22 01 202	TA- SELECTIC NTS PROPHYL ANTRIES SECOND abular Section SECOND abular Section SECOND abstrain SECOND abstrain	ACTIC ACTIC C- FIRST OR GENERATION Measure Name CABG: OP MORT CABG: OP MORT	TOBACCO USE: SCREENING AND CESSATION INTERVENTION_1 INTERVENTION_1 AUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY*	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE: SCREENING AND CESSATION INTERVENTION_3 Performance Not Met Performance Not Met	https:/ https:/ https:/ https:/ https:/ https:/ https:/ https:/
40.00% 20.00% 20.00% CABG: OP (*) Indicates Measures that are do CABG: OP (*) Indicates Measures that are do Measure Name PATIENT-CENTERED RISK ASSESSMENT USING STS RISK CALCULATOR PREOPERATIVE BETA-BLOCKEI IN PATIENTS WITH ISOLATED CABG SURGERY SELECTION OF PROPHYLACTIC ANTIBIOTIC - FIRST OR SECONO-GENERATION	MORTALITY* Time Period O3.2020 O4.2020 O4.2020 O4.2020 O4.2020 C4.2020 O4.2020 O3.2020 O4.2020 O3.2020 O3.2020 O3.2020 O4.2020 O3.2020 O4.2020 O3.2020 O4.2020 O4.20	CABG: PROLONGED INTUBATION* rsc* measures, which Performance Rate 6 .25% 5 .00% 7 5 .00% 7 5 .00% 2 .27% 6 .82% 3 .23% 5 .55% 0 .00%	CABG: PROLONGE LENGTH OF STAV ^a means a lower calculation Eligible Population E 4 20 1 4 4 4 4 62 18 62 18 39	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION ⁴⁴ etter clinical care. In these Performance Met Per 4 1 0 3 0 3 3 0 1 3 2 1 1	PATENT-CENTERED RISK ASSESSMENT USING STS RISK CALCULATOR cases, a performance rote fformance Not Met 60 19 1 1 1 1 0 35 41 60 60 17 39	PREOPERATIVE BE BLOCKER IN PATIEN WITH ISOLATED CA SURGERY closer to 0% is better. Display Case List T Time Period Time Period 01 2020 11 2020 12 2020 11 2020 12 2020 12 2020 12 2020 12 2020 12 2020 12 2020 12 2020 12 2020 12 2020 12 2020 12 2020 12 2020 12 2020 12 2020 11 2020 12 2020 11 2020 12 2020 12 2020 11 2020 12 2020 11 2020 12 2020 11 2020 11 2020 11 2020 11 2020 11 2020 11 2020 11 2020 11 2020 11 2020 11 2020 11 2020 11 2020 11 2020	TA. SELECTICITS ITS PROPHYL BAUTIBIOTS SECOND abular Section SECOND abular Section SESTS1131 SESTS1131 SESTS1131 SESTS1110 SESTS1110 SESTS1110 SESTS1110 SESTS11112 SESTS1113 SESTS1112 SESTS1154 SESTS1154 SESTS154 SESTS154 SESTS154	N OF ACTIC C. FIRST OR GENERATION Measure Name CABG: OP MORT CABG: OP MORT	ТОВАССО USE: SCREENING AND CESSATION INTERVENTION_1 FALITY* FALITY* FALITY* FALITY* FALITY* FALITY* FALITY* FALITY* FALITY* FALITY* FALITY* FALITY* FALITY*	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE: SCREENING AND CESSATION INTERVENTION_3 Performance Status Performance Not Met Performance Not Met	https:/ https:/ https:/ https:/ https:/ https:/ https:/ https:/ https:/
40.00% 20.00% 20.00% CABG: OP CABG: OP (*) Indicates Measures that are di CABG: OP (*) Indicates Measures that are di Measure Name PATIENT-CENTERED RISK ASSESSMENT USING STS RISK CALCULATOR PREOPERATIVE BETA-BLOCKEI IN PATIENT'S WITH ISOLATED CABG SURGRY SELECTION OF PROPHYLACTIC ANTIBIOTIC - FIRST OR	MORTALITY* esignated as "inve Time Period Q3.2020 Q4.2020 Q4.2020 Q3.2020 Q3.2020 Q4.2020 R 01.2020 Q4.2020 Q4.2020 Q4.2020 Q4.2020 Q4.2020 Q4.2020 Q4.2020 Q4.2020	CABG: PROLONGED INTUBATION* rse" measures, which Performance Rate 6.25% 5.00% 75.00% 75.00% 6.82% 3.23% 5.56% 0.00%	CABG: PROLONGE LENGTH OF STAV ^a means a lower calculate Eligible Population E 64 20 1 4 4 0 36 44 62 18 39 67	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION* etter clinical care. In these Performance Met Per 4 0 3 0 3 0 1 3 2 1 1 3 1 1 3 1 1 3 1 1 1 1 0	PATIENT-CENTERED RISKASSESSMENT USING STRISK CALCULATOR et cases, a performance rate formance Not Met 60 19 1 1 1 1 0 35 41 60 17 39 66	PREOPERATIVE BE BLOCKER IN PATIE WITH ISOLATED CA SURGERY closer to 0% is better. Display Case List T Time Period P 0.1 2020 12 0.1 2020 12 0.1 2020 14 0.1 2020 22 0.1 2020 14 0.1 2020 22 0.1 2020 14 0.1 2020 22 0.1 2020 15 0.1 2020 15 0.	TA SELECTIC ITS PROPHY BAUTIBIOT SECOND abular Section Second JASTS1042 SeSTS1104 SESTS1105 SESTS1110 SESTS1110 SESTS1110 SESTS1104 SESTS1104 SESTS104 SESTS104 SESTS102 SESTS102	N OF ACTIC () - FIRST OR GENERATION Measure Name CABG: OP MORI CABG: OP MORI	TOBACCO USE: SCREENING AND CESSATION IINTERVENTION_1 AUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY* FAUTY*	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE: SOREENING AND CESSATION INTERVENTION_3 Performance Not Met Performance Not Met	https:/ https:/ https:/ https:/ https:/ https:/ https:/ https:/ https:/
40.00% 20.00% 20.00% CABG: OP (*) Indicates Measures that are do CABG: OP (*) Indicates Measures that are do Measure Name PATIENT-CENTERED RISK ASSESSMENT USING STS RISK CALCULATOR PREOPERATIVE BETA-BLOCKEI IN PATIENTS WITH ISOLATED CABG SURGERY SELECTION OF PROPHYLACTIC ANTIBIOTIC - FIRST OR SECONO-GENERATION	MORTALITY* sesignated as "Inve esignated as "Inve entities Period (3.2020) (4.2020)	CABG: PROLONGED INTUBATION* rse" measures, which Performance Rate 6.25% 5.00% 75.00% 75.00% 6.22% 3.23% 5.55% 0.00% 1.49% 2.38%	CABG: PROLONGE LENGTH OF STA/* means a lower calculate Eligible Population E 64 20 1 4 4 4 0 36 44 62 18 39 67 67 84	D CABG: RENAL FAILURE	CABG: UNPLANNED REOPERATION* etter clinical care. In these Performance Met Per 4 1 0 3 3 0 1 3 3 0 1 1 3 2 2 1 1 0 1 2 2	PATENT.CENTERED RISKASSESSMENT USING STS RISK CALCULATOR e coses, a performance rote formance Not Met 60 19 1 1 1 1 0 35 41 60 17 39 66 62	PREOPERATIVE BE BLOCKER IN PATIEN WITH ISLOCKER IN PATIEN SURGERY closer to 0% is better. Display Case List T Time Period 01.2020 11 01.2020 21 01.2020 21 01.2020 22 01.2020 22 01.2020 22 01.2020 22 01.2020 22 01.2020 22 01.2020 22 01.2020 22 01.2020 11 01.2020 11	TA. SELECTICITS ITS PROPHYL BAUTIBIOTS SECOND abular Section SECOND abular Section SESTS1131 SESTS1131 SESTS1131 SESTS1110 SESTS1110 SESTS1110 SESTS1110 SESTS11112 SESTS1113 SESTS1110 SESTS1112 SESTS1112 SESTS1112 SESTS1115 SESTS1154 SESTS1054 SESTS11054	N OF ACTIC C. FIRST OR GENERATION Measure Name CABG: OP MORT CABG: OP MORT	TOBACCO USE: SCREENING AND CESSATION INTERVENTION_1 FALITY* ALITY* ALITY* ALITY* ALITY* ALITY* ALITY* ALITY* ALITY* ALITY* ALITY* ALITY* ALITY* ALITY* ALITY* ALITY* ALITY* ALITY*	TOBACCO USE: SOREENING AND CESSATION	TOBACCO USE: SCREENING AND CESSATION INTERVENTION_3 Performance Status Performance Not Met Performance Not Met	https:/ https:/ https:/ https:/ https:/ https:/ https:/ https:/ https:/








IQVIA Support Plan



sts.org





^ Inquiries received outside live support hours will require a 24-hour turnaround window (i.e., one business day) for responses.

Please include your Participant ID

Resources

- STS National Database Webpage
- <u>STSTechSupport@IQVIA.com</u> (Uploader, DQR, Missing Variable, Dashboard, Password and Login)
- Phone Support: 1-833-256-7187
- <u>STS National Database Feedback Form</u>
- Resource Documents
 - Contact Information
 - Webinar Information
 - FAQ Document
 - Go-Live Checklist
 - Tiered-level Support Document
 - Training Videos
 - Link to IQVIA
 - ckrohn@sts.org



Contact Information

- Carole Krohn, Sr. Clinical Manager, STS National Database
 - <u>CKrohn@sts.org</u>
 - 312-202-5847
- Database Operational Questions
 - <u>STSDB@sts.org</u>



Open Discussion

Please use the Q&A Function.

We will answer as many questions as possible.

We encourage your feedback and want to hear from you!